Artificial pancreas with engineered β cell microspheres overexpressing PD-L1 and algae ameliorate type 1 diabetes
Source abstract
Abstract
Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.
Only a short abstract or summary was supplied by the source.
Source: openalex_inverted_index · Quality: short
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Diabetes and associated disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)10.1038/s41574-020-00443-4 ↗
2. Exosome-based drug delivery systems for the treatment of diabetes and its complications: current opinion10.20517/evcna.2023.32 ↗
3. Immune and Pancreatic β Cell Interactions in Type 1 Diabetes10.1016/j.tem.2016.08.007 ↗
4. Immune cell crosstalk in type 1 diabetes10.1038/nri2787 ↗
5. The pathogenic "symphony" in type 1 diabetes: A disorder of the immune system, β cells, and exocrine pancreas10.1016/j.cmet.2023.06.018 ↗
6. Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients10.2337/db22-0557 ↗
7. Treg cell-based therapies: challenges and perspectives10.1038/s41577-019-0232-6 ↗
8. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential10.1016/j.cell.2015.03.030 ↗
9. Depletion of PD-1-positive cells ameliorates autoimmune disease10.1038/s41551-019-0360-0 ↗
10. Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes10.1002/adma.202101253 ↗
11. Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes10.2337/dc22-2202 ↗
12. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy10.18632/oncotarget.25446 ↗
13. Hematopoietic Stem Cells in Type 1 Diabetes10.3389/fimmu.2021.694118 ↗
14. Mesenchymal stem cell-based therapy for type 1 diabetes
15. The role of cytokines and T-bet, GATA3, ROR-γt, and FOXP3 transcription factors of T cell subsets in the natural clinical progression of Type 1 Diabetes10.1007/s12026-022-09355-z ↗
16. Pancreatic Islet Cells Response to IFNγ Relies on Their Spatial Location within an Islet10.3390/cells12010113 ↗
17. Induced regulatory T cells suppress Tc1 cells through TGF-β signaling to ameliorate STZ-induced type 1 diabetes mellitus10.1038/s41423-020-00623-2 ↗
18. Leverage biomaterials to modulate immunity for type 1 diabetes10.3389/fimmu.2022.997287 ↗
19. Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review10.1016/j.ejcb.2023.151329 ↗
20. Review of Advanced Hydrogel-Based Cell Encapsulation Systems for Insulin Delivery in Type 1 Diabetes Mellitus10.3390/pharmaceutics11110597 ↗
21. An injectable and biodegradable zwitterionic gel for extending the longevity and performance of insulin infusion catheters10.1038/s41551-023-01108-z ↗
22. Continuous glucose monitoring: long live the revolution10.1038/ncpendmet1044 ↗
23. Continuous Glucose Monitoring in 201510.1089/dia.2016.2502 ↗
24. Whole-Organ Pancreas and Islets Transplantations in UK: An Overview and Future Directions10.3390/jcm12093245 ↗
25. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen10.1056/NEJM200007273430401 ↗
26. Synergic effects of oxygen supply and antioxidants on pancreatic β-cell spheroids10.1038/s41598-018-38011-6 ↗
27. Strategies for durable β cell replacement in type 1 diabetes10.1126/science.abh1657 ↗
28. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane10.1016/0167-4889(84)90107-1 ↗
29. Encapsulated Islet Transplantation: Where Do We Stand?10.1900/RDS.2017.14.51 ↗
30. Islet transplantation-immunological challenges and current perspectives10.5500/wjt.v13.i4.107 ↗
31. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice10.1126/science.273.5271.109 ↗
32. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice10.4049/jimmunol.1003266 ↗
33. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation10.1016/j.biomaterials.2009.09.045 ↗
34. PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes10.1089/ten.tea.2012.0643 ↗
35. Improved coating of pancreatic islets with regulatory T cells to create local immunosuppression by using the biotin-polyethylene glycol-succinimidyl valeric acid ester molecule. Transplant
36. Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes10.3389/fendo.2020.00569 ↗
37. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes10.1126/scitranslmed.aam7543 ↗
38. Engineered mammalian and bacterial extracellular vesicles as promising nanocarriers for targeted therapy10.20517/evcna.2022.04 ↗
39. Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics10.20517/evcna.2023.58 ↗
40. Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes10.1126/sciadv.adg1082 ↗
41. Engineered Cytokine-Primed Extracellular Vesicles with High PD-L1 Expression Ameliorate Type 1 Diabetes
42. Natural algae-inspired microrobots for emerging biomedical applications and beyond
43. Engineered algae microrobots as photosynthetic living materials promote T cells’ anti-tumor immunity
44. New trends in biotechnological applications of photosynthetic microorganisms10.1016/j.biotechadv.2022.107988 ↗
45. Recent advances in tissue engineering and anticancer modalities with photosynthetic microorganisms as potent oxygen generators10.1016/j.bea.2021.100005 ↗
46. Islet transplantation modulates macrophage to induce immune tolerance and angiogenesis of islet tissue in type I diabetes mice model10.18632/aging.104085 ↗
47. Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome10.1900/RDS.2012.9.385 ↗
48. Engineering β Cell Replacement Therapies for Type 1 Diabetes: Biomaterial Advances and Considerations for Macroscale Constructs10.1146/annurev-pathol-042320-094846 ↗
49. Hydrogels in Emerging Technologies for Type 1 Diabetes10.1021/acs.chemrev.0c01062 ↗
50. Modulating the foreign body response of implants for diabetes treatment10.1016/j.addr.2021.01.011 ↗
51. Domesticating the foreign body response: Recent advances and applications10.1016/j.addr.2019.08.010 ↗
52. Application of Artificial Intelligence in the Exploration and Optimization of Biomedical Nanomaterials10.26599/NBE.2023.9290035 ↗